Early Access — free while we kick the tires
EdgarHawk

Sean Brynjelsen

President & CEO

Director Officer 10% Owner

Latest: President & CEO selling · May 2026

2 filings analyzed · 1 company · Latest 2026-05-29

Companies

Company Buys Sells Direction
Eton Pharmaceuticals, Inc. ETON 0 7 Net selling

Activity

May 2026
high
Sell
120,000 shares
$3,825,717
Significance 6/10

CEO Sean Brynjelsen sells 120,000 shares ($3.8M) at $31.88; stock now down 14.6% from 52-week high despite +79.2% quarterly rally.

Sean Brynjelsen sold 120,000 shares—a 12.6% reduction in his holdings—in 2 separate transactions at prices of $31.88 and $32.67 on 2026-05-28, for a combined $3,825,716.92. The transaction occurred near the 52-week high, with the stock currently trading at $30.45, down 14.6% from its 52-week peak of $35.66 despite a +79.2% gain over 90 days. His prior sells at ETON show a mixed timing pattern: 3 of 5 prior same-ticker sales were well-timed at the 90-day mark (negative returns post-sale), but his cross-ticker track record shows an avg 90d return of -2.1% after 5 prior sells (60% well-timed rate). Against the backdrop of the company's fundamentals—recent quarter revenue of $24,266,000.00 ($24.3M), net income of $1,554,000.00 ($1.6M), but a full-year negative net income and +104.9% annual revenue growth—this substantial CEO sale at cyclical highs warrants attention to whether elevated valuation or forward guidance changes are driving the reduction.

June 2025
high
Sell
210,000 shares
$3,592,611
Significance 6/10

ETON CEO Sean Brynjelsen sold 210,000 shares across 5 trades (June 3-5) for $3,592,611.00, reducing stake by 6.8%

Sean Brynjelsen, President & CEO of Eton Pharmaceuticals, executed 5 separate sales totaling 210,000 shares for $3,592,611.00 between June 3-5, 2025, at prices ranging from $16.81 to $19.02 per share with a blended average of $17.11. The sales reduced his holdings from 3,083,513 shares to 2,873,513 shares, a reduction of 6.8%. This comes at a notable juncture: the stock currently trades at $17.25, only 3.7% above its 30-day average and 14.8% below its 52-week high of $20.25, while the company reported positive revenue growth of 23.3% year-over-year but remains unprofitable with a net loss of $1,572,000 on revenue of $17,282,000 in the latest quarter. The CEO's discretionary sale of a material portion of his stake warrants monitoring given the company's current unprofitable status despite solid top-line growth momentum.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access